Transfer RNA-derived fragments as novel biomarkers of the onset and progression of gastric cancer.
Transfer RNA-derived small RNAs
biomarker
gastric cancer
tRF-18-79MP9P04
tRF-5026a
Journal
Experimental biology and medicine (Maywood, N.J.)
ISSN: 1535-3699
Titre abrégé: Exp Biol Med (Maywood)
Pays: England
ID NLM: 100973463
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
pmc-release:
30
12
2023
medline:
23
10
2023
pubmed:
30
6
2023
entrez:
30
6
2023
Statut:
ppublish
Résumé
Gastric cancer (GC) is a particularly malignant disease; thus, early diagnosis and treatment are especially important. Transfer RNA-derived small RNAs (tsRNAs) have been implicated in the onset and progression of various cancers. Therefore, the aim of this study was to explore the role of tRF-18-79MP9P04 (previously named tRF-5026a) in the onset and progression of GC. Expression levels of tRF-18-79MP9P04 were quantified in gastric mucosa specimens of healthy controls and plasma samples of patients with different stages of GC. The results showed that plasma levels of tRF-18-79MP9P04 were significantly decreased in the early and advanced stages of GC. The results of the nucleocytoplasmic separation assay found that tRF-18-79MP9P04 was localized in the nuclei of GC cells. High-throughput transcriptome sequencing identified genes regulated by tRF-18-79MP9P04 in GC cells, and the function of tRF-18-79MP9P04 was predicted by bioinformatics. Collectively, the findings of this study suggest that tRF-18-79MP9P04 would be useful as non-invasive biomarker for early diagnosis of GC and is related to cornification, the type I interferon signaling pathway, RNA polymerase II activities, and DNA binding.
Identifiants
pubmed: 37387464
doi: 10.1177/15353702231179415
pmc: PMC10583753
doi:
Substances chimiques
RNA, Transfer
9014-25-9
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1095-1102Déclaration de conflit d'intérêts
Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Cancer Lett. 2019 Jun 28;452:31-37
pubmed: 30905816
Mol Ther Nucleic Acids. 2020 Sep 4;21:954-964
pubmed: 32814252
Mol Ther Nucleic Acids. 2021 Jul 02;26:161-173
pubmed: 34513302
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cell Death Discov. 2021 Dec 14;7(1):388
pubmed: 34907180
Neural Regen Res. 2020 Feb;15(2):212-221
pubmed: 31552886
Theranostics. 2021 Jan 1;11(1):461-469
pubmed: 33391486
Int J Mol Sci. 2018 Feb 08;19(2):
pubmed: 29419808
Cell Death Dis. 2021 Dec 21;13(1):24
pubmed: 34934044
Bioengineered. 2022 Feb;13(2):3207-3220
pubmed: 35045793
BMC Biol. 2014 Oct 01;12:78
pubmed: 25270025
Mol Cells. 2019 Oct 31;42(10):687-692
pubmed: 31656062
Mol Aspects Med. 2020 Apr;72:100817
pubmed: 31563278
Int J Oncol. 2010 Apr;36(4):1031-7
pubmed: 20198350
Cancer Biomark. 2020;27(2):243-250
pubmed: 32083573
Transl Lung Cancer Res. 2021 Oct;10(10):3957-3972
pubmed: 34858784
Thorac Cancer. 2021 Sep;12(17):2314-2323
pubmed: 34254739
Lancet. 1975 Jul 12;2(7924):58-60
pubmed: 49653
Front Med. 2022 Apr;16(2):216-226
pubmed: 35416630
J Exp Clin Cancer Res. 2018 May 9;37(1):101
pubmed: 29743091
Signal Transduct Target Ther. 2020 Jun 30;5(1):109
pubmed: 32606362
Ann Plast Surg. 1990 Jul;25(1):26-8
pubmed: 2116113
Stem Cell Res Ther. 2021 Jul 22;12(1):418
pubmed: 34294122
Neural Regen Res. 2020 Jan;15(1):47-52
pubmed: 31535642
NPJ Breast Cancer. 2021 Jan 5;7(1):4
pubmed: 33402674
Cell Mol Life Sci. 2022 Mar 16;79(3):191
pubmed: 35292881